Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow Sells 4,646 Shares

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) General Counsel Adam Dubow sold 4,646 shares of the firm’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the sale, the general counsel now owns 39,602 shares of the company’s stock, valued at $473,639.92. This trade represents a 10.50 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Day One Biopharmaceuticals Trading Up 1.6 %

Shares of NASDAQ:DAWN opened at $12.43 on Monday. The company has a 50 day moving average of $12.37 and a 200 day moving average of $13.48. The stock has a market cap of $1.25 billion, a P/E ratio of -12.07 and a beta of -1.46. Day One Biopharmaceuticals, Inc. has a 12 month low of $11.13 and a 12 month high of $18.07.

Hedge Funds Weigh In On Day One Biopharmaceuticals

Several hedge funds have recently bought and sold shares of the company. FMR LLC grew its stake in Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock valued at $163,284,000 after acquiring an additional 5,475,087 shares in the last quarter. Braidwell LP grew its stake in Day One Biopharmaceuticals by 60.5% during the third quarter. Braidwell LP now owns 4,873,853 shares of the company’s stock valued at $67,893,000 after acquiring an additional 1,837,949 shares in the last quarter. Franklin Resources Inc. grew its stake in Day One Biopharmaceuticals by 0.3% during the fourth quarter. Franklin Resources Inc. now owns 3,882,952 shares of the company’s stock valued at $49,197,000 after acquiring an additional 13,320 shares in the last quarter. Estuary Capital Management LP grew its stake in Day One Biopharmaceuticals by 35.5% during the fourth quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock valued at $47,092,000 after acquiring an additional 972,997 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its position in Day One Biopharmaceuticals by 17.0% during the fourth quarter. Pictet Asset Management Holding SA now owns 3,490,064 shares of the company’s stock valued at $44,219,000 after purchasing an additional 507,398 shares during the last quarter. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the stock. TD Cowen upgraded shares of Day One Biopharmaceuticals to a “strong-buy” rating in a report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $40.00 target price on shares of Day One Biopharmaceuticals in a research note on Thursday, October 31st. The Goldman Sachs Group reduced their target price on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a research note on Monday, February 10th. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a research note on Monday, January 13th. Finally, Bank of America reduced their target price on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.